Osteopenia Treatment Guidelines

Risk Assessment

The American College of Physicians recommends calculating fracture risk using the FRAX tool, which incorporates BMD and clinical risk factors to determine overall fracture risk 1
Pharmacological treatment should be considered when FRAX calculation shows a 10-year risk of hip fracture ≥3% or 10-year risk of major osteoporotic fracture ≥20% 2, 1

The National Osteoporosis Foundation recommends a daily calcium intake of 1,000 mg for ages 19-50 and 1,200 mg for ages 51 and older 2
The American Geriatrics Society recommends a daily vitamin D intake of 600 IU for ages 19-70 and 800 IU for ages 71 and older, with a target serum level of ≥20 ng/mL 2, 1
Regular weight-bearing and muscle-strengthening exercises help improve bone density, according to the National Comprehensive Cancer Network 3, 2
Balance training exercises such as tai chi, physical therapy, and dancing can help reduce fall risk, as recommended by the National Comprehensive Cancer Network 3, 2
Adults should aim for at least 30 minutes of moderate physical activity daily, according to the National Comprehensive Cancer Network 3
Smoking cessation and limiting alcohol consumption (1-2 drinks per day maximum) are recommended by the American College of Physicians 2, 1
Fall prevention strategies including vision and hearing checks, medication review, and home safety assessment are recommended by the National Comprehensive Cancer Network 3
Maintaining weight in the recommended range is recommended by the American College of Physicians 1

Pharmacological treatment is indicated for patients with high fracture risk based on FRAX assessment, according to the American College of Physicians 2, 1
Treatment should be strongly considered in patients with a BMD below a T-score of −2.0, particularly with additional risk factors, as recommended by the National Comprehensive Cancer Network 3
Presence of vertebral fractures significantly increases future fracture risk and warrants treatment consideration, according to the National Comprehensive Cancer Network 3
Oral bisphosphonates (such as alendronate) are recommended as first-line therapy due to safety, cost, and efficacy, according to the American College of Physicians 1
IV bisphosphonates are an alternative therapy for patients who cannot tolerate oral bisphosphonates, as recommended by the American College of Physicians 1
Denosumab is an alternative therapy for patients who cannot tolerate bisphosphonates, according to the American College of Physicians 2, 1
Teriparatide (for high-risk patients) is an alternative therapy, as recommended by the American College of Physicians 1
Selective estrogen receptor modulators (SERMs) are an alternative therapy, according to the National Comprehensive Cancer Network 3

Cancer treatments can accelerate bone loss, particularly those causing hypogonadism, according to the American College of Physicians 2
For cancer survivors with osteopenia and additional risk factors, bisphosphonates or denosumab are preferred agents, as recommended by the American College of Physicians 2
For patients on glucocorticoids, fracture risk should be adjusted by 1.15 for major osteoporotic fracture risk and 1.2 for hip fracture risk if prednisone dose is >7.5 mg/day, according to the American College of Physicians 1
Clinical fracture risk reassessment should be performed every 12 months for patients on glucocorticoids, as recommended by the American College of Physicians 1

Repeat DEXA every 2 years to monitor bone density and treatment response, according to the American College of Physicians 2, 1
Bone mineral density assessment should not be conducted more than annually, as recommended by the American College of Physicians 2, 1

Poor adherence to preventive therapies is common; only 5-62% of patients on glucocorticoid therapy receive appropriate preventive therapies, according to the American College of Physicians 1
Failing to identify and treat secondary causes of osteopenia (vitamin D deficiency, hypogonadism, alcoholism, glucocorticoid exposure) is a common pitfall, as noted by the American College of Physicians 1

Strong risk factors for osteoporosis include oral prednisolone use, hypogonadism, height loss, x-ray evidence of osteopenia, early maternal hip fracture, and low body mass index, as identified by the Gut journal 4
The presence of a fragility fracture indicates severe osteoporosis and warrants treatment without the need for BMD measurement, according to the Gut journal 4

Reduction in alcohol intake is recommended for patients with osteopenia, as suggested by the Gut journal 4
Maintaining adequate nutrition and healthy body weight is essential for patients with osteopenia, as recommended by the Gut journal 4

Anabolic steroids should be avoided in patients with chronic liver disease, as advised by the Gut journal 4
Patients with chronic liver disease should have BMD measurement, as recommended by the Gut journal 4
Ensure adequate nutrition as low body mass index is an independent risk factor for patients with chronic liver disease, according to the Gut journal 4
Supplementation with calcium and vitamin D3 is recommended for patients with chronic liver disease, as suggested by the Gut journal 4

The presence of a fragility fracture indicates severe osteoporosis and warrants treatment without the need for BMD measurement, according to the Gut journal 5
Strong risk factors for osteopenia include oral glucocorticoid use, hypogonadism, height loss, x-ray evidence of osteopenia, early maternal hip fracture, and low body mass index, as reported in the Gut journal 5
Maintaining weight in the recommended range is important as low body mass index is an independent risk factor for osteopenia, according to the Gut journal 5

For patients with chronic liver disease, BMD measurement is recommended, and supplementation with calcium and vitamin D3 is advised, as stated in the Gut journal 5
Cancer treatments can accelerate bone loss, and for cancer survivors with osteopenia and additional risk factors, bisphosphonates or denosumab are preferred agents, according to the Journal of Clinical Oncology 6
Before initiating a bone mineral agent in cancer survivors, a dental screening exam should be performed to reduce the risk of medication-related osteonecrosis of the jaw, as recommended by the Journal of Clinical Oncology 6

When T-scores improve, consider discontinuation of the BMA and follow up with periodic DXA scans, as suggested by the Journal of Clinical Oncology 6
Not considering the risk-benefit profile of medications for individual patients, particularly in those with comorbidities, is a common pitfall to avoid, according to the Annals of Internal Medicine 7